These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23127721)

  • 41. Prostacyclin withdrawal in pulmonary hypertension #264.
    Bartlett C; Landzaat L;
    J Palliat Med; 2013 Feb; 16(2):204-5. PubMed ID: 23336356
    [No Abstract]   [Full Text] [Related]  

  • 42. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
    Humbert M; Barst RJ; Robbins IM; Channick RN; Galiè N; Boonstra A; Rubin LJ; Horn EM; Manes A; Simonneau G
    Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
    Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
    Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epoprostenol for primary pulmonary hypertension.
    Med Lett Drugs Ther; 1996 Feb; 38(968):14-5. PubMed ID: 8592477
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Feasibility of cardiopulmonary rehabilitation in patients with idiopathic pulmonary arterial hypertension treated with intravenous prostacyclin infusion therapy].
    Uchi M; Saji T; Harada T
    J Cardiol; 2005 Nov; 46(5):183-93. PubMed ID: 16320975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol.
    Frost AE; Quiñones MA; Zoghbi WA; Noon GP
    J Heart Lung Transplant; 2005 Apr; 24(4):501-3. PubMed ID: 15797757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endothelin-1 across the lung circulation in patients with pulmonary arterial hypertension and influence of epoprostenol infusion.
    Selimovic N; Andersson B; Bergh CH; Sakiniene E; Carlsten H; Rundqvist B
    J Heart Lung Transplant; 2009 Aug; 28(8):808-14. PubMed ID: 19632577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
    Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
    Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension.
    Findlay JY; Plevak DJ; Krowka MJ; Sack EM; Porayko MK
    Liver Transpl Surg; 1999 Sep; 5(5):362-5. PubMed ID: 10477835
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Education of patients treated with a continuous epoprostenol infusion for pulmonary hypertension].
    Marlier D
    Soins; 2006 May; (705 Suppl):S7-12. PubMed ID: 16771257
    [No Abstract]   [Full Text] [Related]  

  • 52. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
    Gessler T; Seeger W; Schmehl T
    Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
    Mathier MA; McDevitt S; Saggar R
    J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Current status and future prospect of prostacyclin therapy for pulmonary hypertension--intravenous, subcutaneous, inhaled and oral PGI2 derivatives].
    Saji T; Nakayama T; Ishikita T; Matsuura H
    Nihon Rinsho; 2001 Jun; 59(6):1132-8. PubMed ID: 11411125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.
    Horn EM; Barst RJ; Poon M
    Chest; 2000 Oct; 118(4):1229-30. PubMed ID: 11035709
    [No Abstract]   [Full Text] [Related]  

  • 56. Continuous epoprostenol therapy and septal defect closure in a patient with severe pulmonary hypertension.
    Hirabayashi A; Miyaji K; Akagi T
    Catheter Cardiovasc Interv; 2009 Apr; 73(5):688-91. PubMed ID: 19133673
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paradoxical acute thromboembolism during prostacyclin administration.
    Kritz H; Sinzinger H
    Eur Heart J; 1997 Oct; 18(10):1679. PubMed ID: 9347283
    [No Abstract]   [Full Text] [Related]  

  • 58. Overdosing with prostacyclin in primary pulmonary hypertension.
    Wasserman K; Oudiz R
    J Am Coll Cardiol; 2000 Jun; 35(7):1995-6. PubMed ID: 10841256
    [No Abstract]   [Full Text] [Related]  

  • 59. Micrococcus infection in patients receiving epoprostenol by continuous infusion.
    Yap RL; Mermel LA
    Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):704-5. PubMed ID: 14576986
    [No Abstract]   [Full Text] [Related]  

  • 60. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right-heart dysfunction, and refractory hypoxemia after cardiothoracic surgery.
    Muzaffar S; Shukla N; Angelini GD; Jeremy JY
    J Thorac Cardiovasc Surg; 2004 Dec; 128(6):949-50. PubMed ID: 15573083
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.